Noel Clarke
Christie Hospital Foundation Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Noel Clarke as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:06 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05171816 · Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)AstraZeneca · active not recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph3NCT03732820 · Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerAstraZeneca · active not recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:06 UTC. The ranking covers the 200 most relevant of 124 PubMed records, and a shared surname and initials can bring in a namesake. All 124 on PubMed
- 1,573 citationsRCR 55.3
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.N Engl J Med · 20171,453 citationsRCR 50.6
- 1,053 citationsRCR 38.4
- Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.Lancet · 2020345 citationsRCR 16.0
- 324 citationsRCR 10.1
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol · 2018324 citationsRCR 10.1
- 322 citationsRCR 12.5
- 288 citationsRCR 23.1
- Improved outcomes from tertiary center pediatric intensive care: a statewide comparison of tertiary and nontertiary care facilities.Crit Care Med · 1991241 citationsRCR 12.3
- 209 citationsRCR 6.7